Lumbar spine surgery company TranS1 Inc. (NSDQ:TSON) priced a public offering of 6.2 million shares of common stock at $3.25 per share, expecting to raise up to $20.2 million.

TranS1 plans to use the funds for additional clinical trials, reimbursement efforts, sales personnel, research and product development activities and working capital, according to SEC filings. It added that funds may go toward acquisition of or investment in technologies, products or assets that complement the business.

Teladoc announced this week a round of funding totaling $18.6 million, led by Kleiner Perkins Caufield & Byers (KPCB). Other investors in the funding round include Cardinal Partners, HLM Venture Partners, Trident Capital, and New Capital Partners.
Teladoc offers consumers remote consultations with licensed physicians for routine medical issues. The visits are on-demand and can be […]